logo.png
Corbus Pharmaceuticals to Report First Quarter Results on May 11, 2020
May 04, 2020 08:05 ET | Corbus Pharmaceuticals Holdings, Inc.
- Management to host conference call and webcast on Monday, May 11 at 8:30 a.m. ET- NORWOOD, MA, May 04, 2020 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or...
logo.png
Corbus Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2019 Operational and Financial Results on August 8, 2019
August 01, 2019 08:05 ET | Corbus Pharmaceuticals Holdings, Inc.
- Company to host conference call and webcast on Thursday, August 8 at 8:30 a.m. ET - Norwood, MA, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus”...
logo.png
Corbus Pharmaceuticals to Host Conference Call and Webcast to Discuss First Quarter 2019 Operational and Financial Results on May 9, 2019
May 01, 2019 08:05 ET | Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, May 01, 2019 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company focused on treating...
CRBP-300-196.png
Corbus Pharmaceuticals Announces Presentation of Three Abstracts and New Lenabasum Data at 2018 ACR Annual Meeting
September 14, 2018 08:05 ET | Corbus Pharmaceuticals Holdings, Inc.
Lenabasum open-label extension study interim data in systemic sclerosis and dermatomyositis to be presented  Norwood, MA, Sept. 14, 2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings,...
CRBP-300-196.png
Corbus Pharmaceuticals to Present at the Annual B. Riley FBR Healthcare Conference
August 23, 2018 08:05 ET | Corbus Pharmaceuticals Holdings, Inc.
Norwood, MA, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a Phase 3 clinical-stage pharmaceutical company focused on the...
Corbus Pharmaceuticals Reports 2018 First Quarter Financial Results and Provides Business Update
May 10, 2018 08:00 ET | Corbus Pharmaceuticals Holdings, Inc.
– Company continues to make consistent progress in the clinical development programs of lenabasum, in rare, chronic and serious inflammatory and fibrotic diseases – Norwood, MA, May 10, 2018 ...